Generic Name: moxetumomab pasudotox (MOX e TOOM oh mab pa SOO doe tox)
Brand Names: Lumoxiti
Medically reviewed by P. Thornton, DipPharm Last updated on Feb 11, 2019.
What is Lumoxiti?
Lumoxiti (moxetumomab pasudotox) is an injection used to treat hairy cell leukemia.
Lumoxiti is used in adult patients with hairy cell leukemia that has relapsed.
Lumoxiti is also used if the patient has not responded to previous treatments, and has received at least 2 other treatments, including a type of medicine called purine nucleoside analog (PNA).
It is not known if Lumoxiti is safe and effective in children.
Call your doctor right away if you have signs of a rare but serious condition called capillary leak syndrome: dizziness, weakness, cough, trouble breathing, and sudden swelling or weight gain.
Lumoxiti can make you more likely to get infections or may worsen any current infections. Avoid contact with people who have infections that may spread to others (such as chickenpox, measles, flu). Consult your doctor if you have been exposed to an infection or for more details.
Moxetumomab pasudotox can damage your kidneys, especially if you already have kidney disease or if you are 65 years of age or older. Get emergency medical help if you have: unusual bruising or bleeding, fever, confusion, tiredness or irritability, stomach pain, vomiting, dark urine, fast heartbeats, and little or no urination.
Before taking this medicine
To make sure Lumoxiti is safe for you, tell your doctor if you have ever had:
kidney disease; or
a condition that affects your blood and blood vessels (such as hemolytic uremic syndrome or severe thrombotic microangiopathy).
You may need to have a negative pregnancy test before starting this treatment.
Do not use Lumoxiti if you are pregnant. It could harm the unborn baby. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 30 days after your last dose. Tell your doctor right away if you become pregnant.
You should not breast-feed while using Lumoxiti.
How is Lumoxiti given?
Lumoxiti is given as an infusion into a vein. A healthcare provider will give you this injection.
This medicine must be given slowly, and the infusion can take about 30 minutes to complete.
You may be given other medications to help prevent serious side effects or an infusion reaction. Keep using these medicines for as long as your doctor has prescribed.
Lumoxiti is given in a 28-day treatment cycle. You may need to use the medicine only during the first week of each cycle. You may receive up to 6 treatment cycles. Your doctor will determine how long to treat you with this medicine.
During the first 8 days of each treatment cycle, drink up to 12 full 8-ounce glasses of water, milk, or juice every 24 hours.
Lumoxiti dosing information
Usual Adult Dose for Hairy Cell Leukemia:
0.04 mg/kg IV over 30 minutes on Days 1, 3, and 5 of each 28-day cycle for a maximum of 6 cycles, disease progression, or unacceptable toxicity
Recommended Concomitant Treatment:
-Hydrate with 1 L of isotonic solution (e.g., 5% dextrose injection, and 0.45% or 0.9% sodium chloride injection) over 2 to 4 hours before and after each infusion. -Administer 0.5 L to patients under 50 kg.
-Advise patients to hydrate with up to 3 L of oral fluids (e.g., water, milk, or juice) per 24 hours on Days 1 through 8 of each 28-day cycle. In patients under 50 kg, up to 2 L per 24 hours is recommended.
-Premedicate 30 to 90 minutes prior to each infusion with and antihistamine (e.g., hydroxyzine or diphenhydramine), acetaminophen, and a histamine-2 receptor antagonist (e.g., ranitidine, famotidine, or cimetidine).
-Consider oral antihistamines and antipyretics for up to 24 hours following the infusion and an oral corticosteroid (e.g., 4 mg dexamethasone) to decrease nausea and vomiting. Maintain adequate oral fluid intake.
-Monitor fluid balance and serum electrolytes.
-Consider low-dose aspirin on Days 1 through 8 of each 28-day cycle.
-Monitor for thrombosis.
Use: For the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog (PNA)
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your Lumoxiti injection.
What happens if I overdose?
Since this medicine is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.
What should I avoid while receiving Lumoxiti?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Lumoxiti side effects
Get emergency medical help if you have signs of an allergic reaction to Lumoxiti: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your caregiver if you feel dizzy, nauseated, hot or cold, light-headed, or have a headache, muscle pain, cough, trouble breathing, or fast heartbeats.
Lumoxiti can damage red blood cells, which may cause irreversible kidney failure. Get emergency medical help if you have: unusual bruising or bleeding, fever, confusion, tiredness or irritability, stomach pain, vomiting, dark urine, fast heartbeats, and little or no urination.
Call your doctor at once if you have:
low red blood cells (anemia) - pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or
Serious side effects may be more likely in older adults.
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common Lumoxiti side effects may include:
swelling in your arms, legs, or face;
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Lumoxiti?
Other drugs may interact with moxetumomab pasudotox, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Lumoxiti only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2019 Cerner Multum, Inc. Version: 1.01.
More about Lumoxiti (moxetumomab pasudotox)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: miscellaneous antineoplastics
- FDA Approval History